Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Core Insights - Organovo Holdings, Inc. has appointed Norman Staskey as Chief Financial Officer, bringing over 25 years of experience in capital markets and M&A transactions, particularly in the biotech sector [1][2][3] Company Developments - The company’s lead drug, FXR314, has shown promising results in treating liver fibrosis and inflammatory bowel disease (IBD), with significant reductions in liver fat content and improvements in epithelial barrier function in clinical studies [3][4][5] - FXR314 is expected to enter a Phase 2 study targeting moderate to severe ulcerative colitis, with potential for both monotherapy and combination therapy applications [5][6] Technology and Innovation - Organovo utilizes proprietary technology to develop three-dimensional (3D) human tissues that closely mimic native human tissue, enhancing drug development processes [6]